Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ScinoPharm is set to provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data Inc's FDA approved new drug entity Viibryd.
Subscribe to our email newsletter
Viibryd is a novel drug for the treatment of adults with major depressive disorder (MDD).
ScinoPharm president and CEO Jo Shen said beginning from process research through timely development and optimization of long and complicated synthetic processes, they have established a win-win partnership.
ScinoPharm also partners with other leading pharmaceutical companies for custom contract services from clinical materials to commercial.
ScinoPharm is set to expand its CRAM services through its new GMP plant in Changshu, China, which is expected to be operational in Q3 2011, to capture the business opportunities in the rapidly expanding Asian pharmaceutical market.